Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Gheorghiade M, et al. JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. JAMA. 2013. PMID: 23478743 Clinical Trial.
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.
Blood Pressure Lowering Treatment Trialists' Collaboration; Ying A, Arima H, Czernichow S, Woodward M, Huxley R, Turnbull F, Perkovic V, Neal B. Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Lancet. 2015 Mar 7;385(9971):867-74. doi: 10.1016/S0140-6736(14)61171-5. Epub 2014 Nov 4. Lancet. 2015. PMID: 25468168
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.
Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI‐HF Investigators. Dauriz M, et al. J Am Heart Assoc. 2017 Jul 5;6(7):e005156. doi: 10.1161/JAHA.116.005156. J Am Heart Assoc. 2017. PMID: 28679559 Free PMC article. Clinical Trial.
Routine Spironolactone in Acute Myocardial Infarction.
Jolly SS, d'Entremont MA, Pitt B, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel JH, Stanković G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Bhindi R, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Natarajan MK, Schwalm JD, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Asani V, Topic D, Cantor WJ, Bertrand OF, Pourdjabbar A, Yusuf S; CLEAR investigators. Jolly SS, et al. Among authors: pitt b. N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923. Online ahead of print. N Engl J Med. 2024. PMID: 39555814
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV. Chimura M, et al. Among authors: pitt b. JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4613. Online ahead of print. JAMA Cardiol. 2024. PMID: 39550721
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD. Vardeny O, et al. Among authors: pitt b. JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4539. Online ahead of print. JAMA Cardiol. 2024. PMID: 39550716
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
Yang M, Henderson AD, Talebi A, Atherton JJ, Chiang CE, Chopra V, Comin-Colet J, Kosiborod MN, Kerr Saraiva JF, Claggett BL, Desai AS, Kolkhof P, Viswanathan P, Lage A, Lam CSP, Senni M, Shah SJ, Rohwedder K, Voors AA, Zannad F, Pitt B, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Yang M, et al. Among authors: pitt b. J Am Coll Cardiol. 2024 Sep 29:S0735-1097(24)08532-2. doi: 10.1016/j.jacc.2024.09.023. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 39520455 Free article.
Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial.
Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Mc Causland FR, et al. Among authors: pitt b. J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)10252-5. doi: 10.1016/j.jacc.2024.10.091. Online ahead of print. J Am Coll Cardiol. 2024. PMID: 39490700 Free article.
1,239 results